191 related articles for article (PubMed ID: 35204665)
1. Synthesis and Structure-Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents.
Wróbel TM; Rogova O; Sharma K; Rojas Velazquez MN; Pandey AV; Jørgensen FS; Arendrup FS; Andersen KL; Björkling F
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204665
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents.
Wróbel TM; Rogova O; Andersen KL; Yadav R; Brixius-Anderko S; Scott EE; Olsen L; Jørgensen FS; Björkling F
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32660148
[TBL] [Abstract][Full Text] [Related]
3. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
4. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
Garrido M; Peng HM; Yoshimoto FK; Upadhyay SK; Bratoeff E; Auchus RJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():1-10. PubMed ID: 24508512
[TBL] [Abstract][Full Text] [Related]
5. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
7. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
Krug SJ; Hu Q; Hartmann RW
J Steroid Biochem Mol Biol; 2013 Mar; 134():75-9. PubMed ID: 23142656
[TBL] [Abstract][Full Text] [Related]
8. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak EM; Rogers SA; Aubé J; Scott EE
Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
10. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
[TBL] [Abstract][Full Text] [Related]
11. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
Cheong EJY; Nair PC; Neo RWY; Tu HT; Lin F; Chiong E; Esuvaranathan K; Fan H; Szmulewitz RZ; Peer CJ; Figg WD; Chai CLL; Miners JO; Chan ECY
J Pharmacol Exp Ther; 2020 Sep; 374(3):438-451. PubMed ID: 32554434
[TBL] [Abstract][Full Text] [Related]
12. CYP17A1: a biochemistry, chemistry, and clinical review.
Porubek D
Curr Top Med Chem; 2013; 13(12):1364-84. PubMed ID: 23688130
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
Petrunak EM; Bart AG; Peng HM; Auchus RJ; Scott EE
J Biol Chem; 2023 Mar; 299(3):102999. PubMed ID: 36773804
[TBL] [Abstract][Full Text] [Related]
14. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
15. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer.
Wachall BG; Hector M; Zhuang Y; Hartmann RW
Bioorg Med Chem; 1999 Sep; 7(9):1913-24. PubMed ID: 10530940
[TBL] [Abstract][Full Text] [Related]
16. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling.
Pinto-Bazurco Mendieta MA; Negri M; Hu Q; Hille UE; Jagusch C; Jahn-Hoffmann K; Müller-Vieira U; Schmidt D; Lauterbach T; Hartmann RW
Arch Pharm (Weinheim); 2008 Oct; 341(10):597-609. PubMed ID: 18720339
[TBL] [Abstract][Full Text] [Related]
17. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Li A; Yadav R; White JK; Herroon MK; Callahan BP; Podgorski I; Turro C; Scott EE; Kodanko JJ
Chem Commun (Camb); 2017 Mar; 53(26):3673-3676. PubMed ID: 28304025
[TBL] [Abstract][Full Text] [Related]
18. Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Kuzikov AV; Dugin NO; Stulov SV; Shcherbinin DS; Zharkova MS; Tkachev YV; Timofeev VP; Veselovsky AV; Shumyantseva VV; Misharin AY
Steroids; 2014 Oct; 88():66-71. PubMed ID: 24971814
[TBL] [Abstract][Full Text] [Related]
19. Oxazolinyl derivatives of [17(20)E]-21-norpregnene differing in the structure of A and B rings. Facile synthesis and inhibition of CYP17A1 catalytic activity.
Kostin VA; Zolottsev VA; Kuzikov AV; Masamrekh RA; Shumyantseva VV; Veselovsky AV; Stulov SV; Novikov RA; Timofeev VP; Misharin AY
Steroids; 2016 Nov; 115():114-122. PubMed ID: 27505042
[TBL] [Abstract][Full Text] [Related]
20. Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors.
Gumede NJ; Nxumalo W; Bisetty K; Escuder Gilabert L; Medina-Hernandez MJ; Sagrado S
Bioorg Chem; 2020 Jan; 94():103462. PubMed ID: 31818479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
